CARISMA Therapeutics Inc (CARM)
1.23
+0.08
(+6.96%)
USD |
NASDAQ |
Jun 26, 13:58
CARISMA Therapeutics Enterprise Value: -9.572M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | -9.572M |
| June 24, 2024 | -9.987M |
| June 21, 2024 | -14.14M |
| June 20, 2024 | -14.56M |
| June 18, 2024 | -13.73M |
| June 17, 2024 | -13.73M |
| June 14, 2024 | -9.156M |
| June 13, 2024 | -7.91M |
| June 12, 2024 | -7.91M |
| June 11, 2024 | -5.002M |
| June 10, 2024 | -1.263M |
| June 07, 2024 | -11.65M |
| June 06, 2024 | -10.40M |
| June 05, 2024 | -8.741M |
| June 04, 2024 | -7.079M |
| June 03, 2024 | -2.510M |
| May 31, 2024 | -1.263M |
| May 30, 2024 | -2.094M |
| May 29, 2024 | -2.925M |
| May 28, 2024 | -0.8478M |
| May 24, 2024 | -0.4324M |
| May 23, 2024 | -4.171M |
| May 22, 2024 | 2.060M |
| May 21, 2024 | 2.476M |
| May 20, 2024 | 2.060M |
| Date | Value |
|---|---|
| May 17, 2024 | 2.060M |
| May 16, 2024 | 0.3985M |
| May 15, 2024 | 1.645M |
| May 14, 2024 | 4.137M |
| May 13, 2024 | 4.968M |
| May 10, 2024 | 4.968M |
| May 09, 2024 | 6.214M |
| May 08, 2024 | 7.876M |
| May 07, 2024 | 7.876M |
| May 06, 2024 | 9.746M |
| May 03, 2024 | 10.78M |
| May 02, 2024 | 9.953M |
| May 01, 2024 | 11.20M |
| April 30, 2024 | 11.20M |
| April 29, 2024 | 12.86M |
| April 26, 2024 | 11.62M |
| April 25, 2024 | 11.62M |
| April 24, 2024 | 13.28M |
| April 23, 2024 | 14.11M |
| April 22, 2024 | 21.17M |
| April 19, 2024 | 11.20M |
| April 18, 2024 | 14.52M |
| April 17, 2024 | 13.69M |
| April 16, 2024 | 14.11M |
| April 15, 2024 | 16.60M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-25.45M
Minimum
Apr 10 2023
265.08M
Maximum
Jul 14 2023
57.93M
Average
27.17M
Median
Feb 29 2024
Enterprise Value Benchmarks
| Verastem Inc | 26.78M |
| Aquestive Therapeutics Inc | 143.88M |
| Gritstone Bio Inc | 72.21M |
| Black Diamond Therapeutics Inc | 148.70M |
| Moderna Inc | 44.21B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.98M |
| Revenue (Quarterly) | 3.397M |
| Total Expenses (Quarterly) | 22.91M |
| EPS Diluted (Quarterly) | -0.46 |
| Profit Margin (Quarterly) | -558.7% |
| Earnings Yield | -159.3% |
| Normalized Earnings Yield | -159.35 |